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The polycystic ovary syndrome (PCOS) is one of the most frequent endocrinopathies in women. Its incidence is assessed at 6–8%
of the female population in the reproductive age. It is characterised by oligomenorrhea (Oligo), hyperandrogenism (HA), and the
presence of polycystic ovaries (PCOs). Carbohydrate and lipid metabolism is being disturbed in many women with PCOS. The
pathogenesis of PCOS is still unexplained. Following the main criteria of diagnosis (Rotterdam Consensus 2003), Dewailly, Welt
and Pehlivanov divided the patients with PCOS into 4 phenotype groups: A, B, C, and D. In our studies of 93 patients with PCOS,
we found (1) the most frequent appearance (60,2%) of the phenotype A [Oligo + HA + PCO]; (2) an increased androstenedione
concentration in a group with HA (A, B, C); (3) an increased HOMA-β and insulin concentration after 30min an oral 75g glucose
tolerance test (OGTT) in a group of obese women with BMI > 30kg/m2; (4) high levels of total testosterone, total cholesterol,
and LDL cholesterol concentrations in a group A with classic phenotype of PCOS: Oligo + HA + PCO—increasing the risk of
development of cardiovascular diseases, type 2 diabetes, or metabolic syndrome. The average androstenedione concentrations
could be a good diagnostic and prognostic parameter.
1.Introduction
Polycystic ovary syndrome (PCOS) is one of the most
commonfemaleendocrinedisordersaﬀectingapproximately
6–8% of women in the reproductive age. It is one of the
maincausesofinfertilityresultingfromchronicanovulation.
Thissyndromewasﬁrstdescribedin1935byStein-Leventhal
who observed among some patients menstrual disorders and
polycystic ovaries (the “billiard ball” sign on ultrasound
examination) [1]. The most common irregularities of PCOS
include elevated serum levels of free testosterone (T),
androstenedione, dehydroepiandrosterone sulfate (DHEAS),
excessive amount of luteinizing hormone (LH), elevated
LH/FSH ratio, increase in LH peak pulse frequency and its
response to GnRH (Gonadotropin-releasing hormone), and
change in LH pulse frequency. Insulin resistance, obesity,
dyslipidemia, elevated laboratory ﬁndings associated with
inﬂammation, high blood pressure, and increased risk of
cardiovascular diseases are the common symptoms of PCOS.
Albeit the research trials are broad, the pathogenesis remains
uncertain.
1.1. Criteria for Deﬁning PCOS. In 1990, a consensus
workshop sponsored by the NIH/NICHD [2, 3], PCOS was
deﬁned as: menstrual disorders and hyperandrogenism after
exclusion of other endocrine disorders such as hyperpro-
lactinemia, thyroid gland disorders, and congenital adrenal
hyperplasia. At the conference in Hamburg [2], the addi-
tional diagnostic criteria for PCOS were added: acne,
hirsutism, elevated blood levels of androgens, and increased
insulin resistance. Today’s deﬁnition of PCOS was deﬁned
by a consensus workshop sponsored by ESHRE/ASRM in
Rotterdam in May 2003 [4]. It includes
(1) menstrual disorders (oligoovulation/anovulation),
(2) clinical and/or biochemical evidence of hyperandro-
genism,2 ISRN Endocrinology
Table 1
Phenotypical groups: A B C D
Menstrual disorders (Oligo) + + +
Clinical and/or biochemical
hyperandrogenism (HA) +++
Polycystic ovaries (PCO) + + +
Table 2
I II III
Menstrual disorders (Oligo) + + +
Biochemical hyperandrogenism (HA-b) + +
Clinical hyperandrogenism (HA-c) + +
(3) polycystic ovaries on ultrasound examination (at
least 10 follicles 2–9mm in size or volume of the
ovary greater than 10mL).
In 2005, Azziz introduced modiﬁcation of NIH criteria
forPCOSregardingandrogenexcessandovariesdysfunction
(irregularity or absence of menses accompanied with visual-
ization of polycystic ovaries) [5].
1.2. Phenotype. Regarding the Rotterdam criteria for PCOS
[4,6],bothendocrinalandclinical,wedistinguish4diﬀerent
phenotypes of the syndrome, as shown in Table 1:
(A) Oligo + HA + PCO,
(B) Oligo + HA,
(C) HA + PCO,
(D) Oligo + PCO.
In 2005, Chang et al. [5] proposed another division of the
phenotype into 3 groups (See Table 2).
(I) Oligo + HA biochemical + hirsutism,
(II) Oligo + HA biochemical,
(III) Oligo + hirsutism.
In the similar manner, Hassa et al. [7] introduced resembling
division of PCOS’s phenotype into 3 groups (See Table 2).
(I ) Oligo + HA clinical and biochemical,
(II ) Oligo + HA biochemical,
(III ) Oligo + HA clinical.
1.3. Objective. The objective of the study was to deﬁne
hormonal, biochemical, and metabolic abnormalities among
women with PCOS arising from a group of 4 standard
phenotypesandthentoidentifycoexistenceofendocrineand
biochemical abnormalities in 4 groups of patients who are at
increased risk of metabolic diseases.
2.MaterialandMethods
We identiﬁed 93 women who met the current ESHRE/ASRM
criteria for PCOS [4, 6] and evaluated their hormonal and
biochemical proﬁles. The physical examination included
measurements of circumferences of their waist and hips
and calculation of the body mass index (BMI). We also
evaluated the extent of hyperandrogenism (hirsutism—
using the Ferriman Gallwey hirsutism evaluation system [8];
acne—using the subjective 0–10 scale) and used both: the
insulin resistance index HOMA-IR with HOMA-β-cell index
(assessing beta-cell function) and QUICK (Quantitative
Insulin Sensitivity Check) index, regarding insulin resistance
[5]:
HOMA-IR index =
(Io × Go)
22,5
,
HOMA-β-cell index =
(20 × Io)
((Go × 0,05551) −3,5)
,
QUICK index =
1 
log(Io)+l o g (Go)
.
(1)
The above formulas refer to the fasting levels of glucose
[mg/dL] (Go) and insulin [μU/mL] (Io).
The presented results were prepared by classifying the
women into four groups (Rotterdam Study) according to
their phenotype (A, B, C, D) [4, 6]. The obtained results
were analyzed in terms of these 4 groups and additionally in
terms of three basic groups that include menstrual disorders
(oligoovulation/anovulation), clinical and/or biochemical
evidence of hyperandrogenism, and polycystic ovaries on
ultrasound examination.
In each patient, we determined the serum levels of high-
sensitivity C-reactive protein (hsCRP), androgens: testos-
terone, androstenedione, dehydroepiandrosterone sulfate,
estradiol (E2), 17-hydroxyprogesterone (17-HOP), LH, FSH
(follicle-stimulating hormone), sex hormone binding glob-
ulin (SHBG), lipids, aminotransferases, glucose and insulin
fasting and after ingestion of 75g glucose (measurements
in 30th, 60th, and 120th min after 75g glucose ingestion).
An ultrasound examination of the reproductive system, in
particular the ovaries, was performed on each patient. The
examinations were carried out during the ﬁrst phase of the
menstrual cycle (1st–10th day of the cycle) in all women
with PCOS, except for the patients who had been taking
medications for any reason during the last 3 months.
In the recruiting process, we had to exclude the patients
with coexisting thyroid gland disorders, diabetes mellitus,
ovarian and adrenal tumors, congenital adrenal hyperplasia,
and other important pathologies. We determined the serum
levels of thyroid-stimulating hormone (TSH), adrenocor-
ticotropic hormone (ACTH), 17-hydroxyprogesterone (17-
HOP), and metoclopramide-stimulated prolactin (PRL)
serum levels. We also performed the ultrasound examination
both of the thyroid gland and abdominal cavity, chest
radiography, collection of 24-hour urine steroids derivatives:
17-hydroxycorticosteroids (17-OHCS) and 17-ketosteroids
(17-KS)intermsofnormalproductionandsuppressionwith
small amount of Dexamethasone (4 × 0,5mg) for two days.ISRN Endocrinology 3
Diagnostic criteria for diabetes mellitus were based on
the fasting serum glucose level and serum glucose level in
the oral glucose tolerance test (OGTT) after a 75g glucose
load. The serum level of 17-OHP above 5mg/dL was highly
suspicious for the congenital adrenal hyperplasia. The tests
were repeated for the results above 3.5mg/dL.
The diagnosis of the thyroid gland disorders was estab-
lished by determining TSH, free thyroxine (FT4), and
antithyroid autoantibodies. The diagnosis of the hirsutism
was established by gathering at least six points using the
Ferriman Gallwey hirsutism evaluation system. Acne was
diagnosed in these patients who received four or more
points using the subjective 0–10 scale, in which we assessed
face, back, and other body parts (max. 20 points). Blood
was collected from the fasting patients in the morning.
They were between 1st and 10th day of their menstrual
cycle. The hormonal blood tests were performed by using
both radioimmunoassay (RIA) and IRMA methods and
immunochemiluminescent method with the Immulite 2000
(Dpc, Los Angeles, Ca) device at the Endocrine Clinic of
Medical Centre of Postgraduate Education (CMKP).
Normality of analyzed variables was tested with Saphiro-
Wilk test. Comparisons between groups were performed by
ANOVA or Kruskal-Wallis tests. To compare two indepen-
dent groups of observations, Mann-Whitney U test has been
used. The signiﬁcance level alpha was chosen at 0,05. The
statistical analysis was performed using Statistica 9.0PL.
3. Results
The most common phenotype was phenotype A (60,2%,
P<0,05). Phenotype A met all 3 current criteria for the
PCOS. Its prevalence was similar to the numbers quoted by
other authors (58,6%–71%) [9–11]. The other three pheno-
typical groups appeared signiﬁcantly more rarely, namely, C
(18,3%), B (16,1%), and D (5,4%), and, according to three
other authors, their prevalence was diﬀerent (Table 3).
TheprevalenceofthePCOSinthreephenotypicalgroups
in our trial was comparable to the results presented by
Chang and Hassa et al. [5, 7]. The most common patients
were those who met all three diagnostic criteria for the
PCOS, although there were some diﬀerences in the per-
centages among the cited authors (I-69,7%, I -84,85%). The
diﬀerences could have resulted from the numeral diﬀerences
among test populations and the diagnostic criterion for the
hyperandrogenism aﬀecting the prevalence of acne.
The presented trial did not show the statistical signiﬁ-
cance in the diﬀerences such as patients’ average age, weight,
height, circumference of waist and hips, waist to hip ratio,
and body mass index (P>0.05), among the four described
phenotypical groups (A, B, C, D). Although there were
signiﬁcant statistical diﬀerences regarding the average ovary
volume, prevalence of hirsutism, acne, and the length of the
menstrual cycle (P<0,05), which was in compliance with
the recruitment and classiﬁcation of the individuals to the
speciﬁc phenotypical groups (Table 4).
The highest serum levels of testosterone and dehy-
droepiandrosterone sulfate (DHEAS) were observed in
women who presented clinical evidence of hyperandro-
genism (groups A, B, and C) (Table 5). Analyzing each
group with the hyperandrogenism alone, the levels of serum
testosterone were statistically higher (P<0,04) in the group
A, comparing to the group D. Despite the observed higher
levels of serum testosterone in the group B and C, the B/D
correlation was not statistically signiﬁcant. However, there
were observed statistically higher levels (P<0,05) of serum
testosterone and DHEAS in the group C in comparison to
thegroupwithoutthesignsofhyperandrogenism(groupD).
The levels of androstenedione were very clearly elevated (P<
0,004) in all three groups with hyperandrogenism (A, B, C),
when comparing them to the group D—without the signs of
hyperandrogenism. Similarly, when we compare each group
with the hyperandrogenism, the levels of androstenedione
were statistically signiﬁcantly higher (A/D P<0,005; B/D
P<0,013; C/D P<0,004). Although the highest levels
of androstenedione were present in the phenotypical group
B (mean 525,17ng/dL ±146,08ng/dL) which presents no
morphological signs of polycystic ovaries on ultrasound
examination, the androstenedione B group levels were
signiﬁcantly higher than in the group C (P<0,05).
Similarly to androstenedione, the levels of 17-HOP were
signiﬁcantly higher (P<0,03) in all three groups with
hyperandrogenism (A, B, C), when compared to the group D
(Table 5). A resembling, statistical correlation was observed
when the levels of 17-HOP in the group A and D were
compared (P<0,02).
The higher levels of LH and estradiol (E2) were observed
in the group A in comparison to the group C (without
menstrual disorders) and the average value of the parameters
diﬀered in the statistical signiﬁcance (P<0,05). The
highest average levels of LH and E2 were detected in
the group B (without morphological signs of PCOS on
ultrasound examination), although these results were not
signiﬁcant, probably because of the greater variability of
these parameters in both groups.
The elevated values of the LH/FSH ratio were noticed
among women in the group A and C when compared to
the group D (without hyperandrogenism). Because of the
small number of women in the group D, this remark was not
statistically proven and has been left as the object of further
investigation.
There were no statistical signiﬁcant diﬀerences between
the presented phenotypical groups B, C, and D regard-
ing total cholesterol, HDL-cholesterol, LDL-cholesterol, or
triglyceride levels. However, the levels of total cholesterol
(184,23±33,86 versus 165,12±23,50mg/dL; P<0,05) and
LDLcholesterol(103,14±29,35versus87,02±21,40mg/dL;
P = 0,04) were signiﬁcantly higher in the group A
comparing to the three other groups.
Thegreatestlevelsof17-KSinurine(steroidmetabolites)
were measured in the group C without menstrual disorders
(17,28 ± 4,2mg/dL, norm: 4,2–16.3mg/dL). The diﬀerence
between the levels of 17-KS in urine in the group C and the
groups A, B, and D was of the statistical signiﬁcance (P<
0,05).
The higher levels of 17-OHCS in urine were observed
in the groups B and D, in which the obese women (BMI4 ISRN Endocrinology
Table 3: Prevalence of 4 phenotypical groups (A, B, C, D) in the PCOS.
Prevalence of PCOS
Dewailly et al. —France [9] W e l te ta l .— B o s t o n / I c e l a n d[ 10] Pehlivanov and Orbetzova —Bulgary
[11]
Group (no.) 93 406 418 70
Phenotype A 60,2% 60,6% 71% 58,6%
Phenotype B 16,1% 6,7% 2% 11,4%
Phenotype C 18,3% 16,5% 18% 10,0%
Phenotype D 5,4% 16,3% 9% 20,0%
Table 4: Features of the individuals with PCOS, classiﬁed to 4 phenotypical groups (A, B, C, D).
Phenotypical group AB C D
Oligo + HA + PCO Oligo + HA HA + PCO Oligo + PCO
Number of individuals 56 15 17 5
Average age (years) 24,3 ±4,5 21,9 ±4,8 24,6 ±5,1 24,0 ±7,0
Age 15–20 years 6(10,7%) 6(40%) 2 (11,8%) 2(40%)
Age 20–25 years 35(62,5%) 7 (46,7%) 11 (64,7%) 1(20%)
Age 25–30 years 9(16,1%) 02 (11,8%) 2(40%)
Age > 30 years 6(10,7%) 2 (13,3%) 2 (11,8%) 0
BMI (kg/m2) 26,22 ±7,1 28,95 ±7,2 26,12 ±6,5 28,38 ±8,6
Weight (kg) 71,6 ±19,3 82,1 ±22,3 75,2 ±19,9 80,8 ±17,7
Height (cm) 165,3 ±6,9 168 ±5,15 169,6 ±4,0 169,8 ±7,4
Circumference of waist (cm) 81 ±14,6 86,4 ±14,0 81,1 ±13,3 87,8 ±13,08
Circumference of hip (cm) 103 ±12,9 110,1 ± 16,5 104,8 ±11,7 107 ±6,36
Circum. waist/hip index 0,78 ±0,06 0,78 ±0,05 0,77 ±0,06 0,82 ±0,07
Average ovary volume (mL) 14,08 ±4,01 6,9 ±1,93 13,31 ±3,61 11,63 ±2,15
Hirsutism 43(76,8%) 11 (73,3%) 12 (70,6%) 0
Acne 32(57,1%) 13 (86,7%) 11 (64,7%) 0
Average cycle length (days) 91,7 ±44,82 35 ±6,0 30,8 ±1,12 35,5 ±0,7
Cycle length 27–34dni (%) 00 1 7 (100%) 0
Cycle length 35–44dni (%) 11 (19,6%) 9(60%) 04 (80%)
Cycle length 45–90dni (%) 22 (39,3%) 4 (26,7%) 04 (20%)
Cycle length > 90dni (%) 24 (41,1%) 2 (13,3%) 00
Each value represents mean ± standard error of mean or number of cases (percentage).
30kg/m2 and greater) predominated (P<0,003), in
comparison to the groups A and C (in which there was a
slight majority of slim women; BMI <27kg/m2).
In the observed population, the lowest levels of insulin
in 30th minute after 75g glucose load (OGTT) were seen
among women in the group A and the levels were statistically
lower (P<0,001) in comparison to the other three groups
(B, C and D), where there was the biggest percentage of
obese women(BMI>30kg/m2).Similar resultswerenoticed
regarding fasting insulin, but they could not be conﬁrmed
statistically (Table 6).
The highest levels of insulin in 30th minute (94,44 ±
50,27uU/mL) were present in the groups B and D with the
biggest percentage of the obese women (P<0,0005) when
compared to the groups A and C (51,66 ± 25,84uU/mL).
The index HOMA-β that assesses beta-cell function was
statistically higher in the groups B and D in comparison to
the groups A (P<0,05) and A+C (P<0,01). However, the
indexes HOMA-IR and QUICK index showed no statistical
signiﬁcance.
4. Discussion
The presented division into four standard phenotypical
groups(ESHRE/ASRM)signiﬁcantlyemphasizestheexisting
diﬀerences in PCOS, which is not a homogenous disorder
but the unit of three coexisting elements: menstrual disorder,
hyperandrogenism, and presence of the polycystic ovaries
[4, 6]. Moreover, we all observed disorders in lipid and
carbohydrate metabolism. Our analysis of 93 women with
the PCOS showed that the elevated levels of insulin in
the 30th minute after 75g glucose load in the groupISRN Endocrinology 5
Table 5: The serum levels of the hormones in women with POCS divided into 4 phenotypical groups (A, B, C, D).
Type phenotype AB C D
Oligo + HA + PCO Oligo + HA HA + PCO Oligo + PCO
Testosterone (ng/mL) 0,88 ±0,31 0,78 ±0,15 0,76 ±0,3 0,55 ±0,1
SDHEA (ng/mL) 3566,84 ± 1203,61 3568,33 ±1481,27 4327,75 ±1514,1 2161,00±974,4
Androstenedione (ng/dL) 485,28 ±146,60 525,17 ±146,08 395,25 ±67,7 192,00 ±103,2
17-hydroxyprogesterone (ng/mL) 2,04 ±0,82 1,78 ±0,74 1,74 ±0,9 0,75 ±0,5
Estradiol (pg/mL) 47,77 ±14,30 54,9 ±30,5 37,63 ±11,9 39,25 ±0,6
LH (U/L) 9,74 ±4,60 11,30 ± 11,6 6,10 ±3,3 4,99 ±2,3
FSH (U/L) 6,64 ±1,64 6,45 ±2,73 6,10 ±1,3 5,94 ±1,7
LH/FSH 1,55 ±0,83 1,55 ±0,83 1,05 ±0,7 0,93 ±0,6
SHBG (nmol/L) 47,60 ±32,59 39,5 ±29,4 44,29 ±24,3 39,00 ±10,1
Prolactin (μg/L) 15,08 ±7,58 17,28 ± 6,47 18,43 ±5,3 25,50 ±10,6
TSH (μIU/mL) 2,08 ±0,99 2,39 ±1,57 1,26 ±0,7 1,60 ±0,6
FT4 (pmol/L) 17,80 ±1,70 17,2 ±2,62 19,68 ±3,1 15,80 ±2,0
ACTH (pg/mL) 25,08 ±11,37 29,0 ±15,1 47,88 ±17,7 29,00 ±8,5
Cortisol (μg%) 15,21 ±3,72 18,73 ± 7,99 20,93 ±5,5 18,45 ±0,9
17-hydroxycorticosteroids (mg/dL) 5,23 ±1,71 7,04 ±1,59 5,54 ±1,6 7,40 ±1,3
17-ketosteroids (mg/dL) 16,45 ±4,94 17,28 ± 3,56 20,78 ±4,2 18,85 ±8,3
Mean ± standard error of mean.
Table 6: Risk of metabolic disorders in women with PCOS divided into 4 phenotypical groups (A, B, C, D) based on biochemical, hormonal
and proper indexes.
Phenotypical group AB C D
Oligo + HA + PCO Oligo + HA HA + PCO Oligo + PCO
Fasting insulin (uU/mL) 7,67 ±5,49 9,71 ±4,39 8,25 ±3,33 8,50 ±6,36
Insulin after 30min of OGTT 47,59 ±24,20 97,43 ±57,08 64,88 ±28,19 84,00 ±19,80
Insulin after 60min of OGTT 61,04 ±46,02 71,29 ±29,12 51,88 ±42,31 97,00 ±9,90
Insulin after 120min of OGTT 43,22 ±43,75 37,14 ±29,62 22,88 ±13,24 76,50 ±33,23
Fasting Glucose (mg/dL) 87,68 ±11,94 82,37 ±10,45 84,40 ±8,93 80,00 ±7,07
Glucose in 30min of OGTT 142,70 ±20,38 132,40 ±26,20 120,10 ±32,70 134,50 ±7,78
Glucose in 60min of OGTT 129,65 ±47,24 107,17 ±13,19 94,68 ±35,11 136,00 ±11,31
Glucose in 120min of OGTT 105,38 ±38,53 92,67 ±39,22 86,93 ±16,90 114,00 ±7,07
HOMA-IR index 1,77 ±1,49 2,04 ±0,93 1,78 ±0,80 1,73 ±1,40
HOMA-β index 110,89 ±55,23 167,14 ±80,71 128,78 ±34,25 167,01 ±65,61
QUICK index 0,38 ±0,05 0,35 ±0,03 0,36 ±0,02 0,37 ±0,05
Peptide C (ng/mL) 2,09 ±0,86 2,42 ±1,05 1,58 ±0,87 2,84 ±0,20
HsCRP (mg/L) 2,00 ±1,81 1,76 ±1,56 1,50 ±1,08 2,59 ±0,24
Cholesterol (mg/dL) 184,23 ±33,86 169,67 ±20,03 166,70 ±12,28 159,00 ±38,18
HDL (mg/dL) 61,74 ±17,60 64,24 ±29,77 59,81 ±15,59 59,90 ±1,98
LDL (mg/dL) 103,14 ±29,35 87,64 ±26,14 92,43 ±14,02 81,00 ±24,04
Trigliceryde (mg/dL) 96,64 ±56,78 107,13 ±65,56 80,33 ±36,73 92,00 ±62,23
BMI (kg/m2) 26,22 ±7,1 28,95 ±7,2 26,12 ±6,5 28,38 ±8,6
BMI < 20% 15,38% 14,29% 12,5% 0
BMI 20–25% 34,62% 14,29% 50,0% 50,0%
BMI 25–30% 26,92% 28,57% 12,5% 0
BMI > 30% 23,08% 42,86% 25,0% 50,0%6 ISRN Endocrinology
Oligo + HA (B) in comparison to the average insulin level in
the 30th min in the group of women who do not present the
polycystic ovaries on the ultrasound examination (A, C, and
D) may be related to slightly increased prevalence of obesity
and hypertriglyceridemia among these individuals.
Similar observations were noticed regarding beta-cell
function index (HOMA-β), which reached the highest levels
in the groups B and D, when compared to the groups A
and AC, which seems to be connected with the obesity
prevalence.
The levels of indexes HOMA-IR and QUICK, regarding
the insulin resistance, showed no statistical signiﬁcance
in the analyzed groups, although there was some upward
tendency of the HOMA-IR index accompanied by decrease
of the QUICK index in the groups B and D, with the
elevated number of obese women. This data requires further
investigation.
In the analyzed groups, there were no statistically signiﬁ-
cant diﬀerences among the presented phenotypical groups B,
C,andDwhenitcomestototalcholesterol,HDLcholesterol,
LDL cholesterol, or triglycerides, although the levels of total
cholesterol and LDL cholesterol were commonly higher than
normal, especially in the phenotypical group A (21 of 56
individuals), which is suggestive of intensiﬁcation of dysreg-
ulation and increased risk of cardiovascular and metabolic
diseases among women with complete phenotype of PCOS.
The major amount of abnormalities in the phenotypical
group A was also seen by other authors [9–11].
The androstenedione levels were clearly elevated in
all three groups with hyperandrogenism (A, B, C), when
compared to the group D without the signs of hyperandro-
genism. When we compared particular groups with hyper-
androgenism, the levels of androstenedione were statistically
signiﬁcantly higher. That is why the measurement of the
androstenedione levels seems to be a crucial diagnostic and
predictive factor among women with menstrual disorders or
present polycystic ovaries of ultrasound examination. The
elevatedserumlevelsofandrostenedioneinthegroupB,with
no sign on polycystic ovaries on ultrasound examination,
in comparison to the phenotypical group C, require further
investigation.
The higher than normal levels of 17-KS in urine in group
C (without menstrual disorders) could be a sign of increased
role of the ovaries in the androgen production in this group,
when compared to the other groups with such disorders (A,
B, D). Nevertheless, further studies are necessary.
The greatest levels of 17-OHCS in urine were observed in
the groups B and D (in which the obese women with BMI
> 30kg/m2 predominated) when compared to the groups A
and C. This might indicate the greater role of the adrenal
gland in the androgen production among obese women and
the increased risk of the insulin resistance in the group of
obese individuals with PCOS.
5. Conclusions
In the performed study regarding 93 women with the PCOS,
the following correlations were determined.
(1) The major prevalence of the phenotypical group A,
which is similar to the result presented by the other
authors.
(2) The increased level of androstenedione strongly cor-
relates with the clinical degree of hyperandrogenism.
It seems that androstenedione could be a crucial
diagnostic and predictive factor among women with
menstrual disorders or presence of polycystic ovaries
on ultrasound examination.
(3) The elevated levels of the indexes that correlate with
the degree of insulin resistance such as the beta-
cell function index (HOMA-β) or insulin level in
30th min, after 75g glucose load, are met more
often among obese women with BMI > 30kg/m2,
rather than in slim individuals, without coexisting
hyperandrogenism or presence of polycystic ovaries
on ultrasound examination.
(4) In the phenotypical group A, there were noticed
elevated levels of total testosterone, androstenedione,
and signiﬁcantly higher levels of total cholesterol and
LDL cholesterol. It may point out the increased risk
of cardiovascular and metabolic diseases. Because of
thesmallnumberofwomenintheinvestigatedgroup
and too short a period on the trial, this thesis needs
to be the subject of further studies.
The presented division into four phenotypical groups
and the observed correlations contribute to the greater
understanding of the core of the polycystic ovary syndrome
and to the better recognition of its pathogenesis.
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